On March 21, the Court of Appeals for the Federal Circuit held in a precedential opinion that legal fees incurred by generic drug companies in defending against patent infringement suits brought under the Hatch-Waxman Act...more
3/26/2025
/ Abbreviated New Drug Application (ANDA) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Internal Revenue Code (IRC) ,
IRS ,
Litigation Fees & Costs ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Industry ,
Precedential Opinion ,
Tax Deductions